Eli Lilly Acquires Psychedelic Medicine Biotech AtaiBeckley
Eli Lilly has agreed to acquire clinical-stage biotech company AtaiBeckley for up to $3.8 billion, including a potential milestone payment of $1 billion after an initial $2.8 billion upfront. The acquisition aims to expand Eli Lilly's neuroscience portfolio with psychedelic-based therapies in development.
Topics: biotech GLP-1 drugs mental health therapies pharmaceuticals